Davidson Michael H.'s Form 4 filing
NewAmsterdam Pharma Co N.V.NAMS · filed Mar 28, 2025
- Accession no.
- 0000950170-25-046934
- Filed
- Mar 28, 2025
- Trade date
- Mar 26, 2025
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 3 non-derivative transactions and 2 derivative transactions. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Davidson Michael H.CIK 0001573785 | Director, Officer (Chief Executive Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 26, 2025 | Ordinary Shares | AGrant or awardAcquired | +30,992 | $0.00 | $0 | 364,305 | Direct | |
| Mar 26, 2025 | Ordinary Shares | MOption exerciseAcquired | +38,394 | $0.00 | $0 | 402,699 | Direct | |
| Mar 26, 2025 | Ordinary Shares | SSaleDisposed | −12,258 | –F3 | – | 390,441 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F3
These shares were sold in multiple transactions at a price ranging from $22.88 to $23.22 per share. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities Exchange Comission, upon request, full information regarding the number of shares sold in each transaction.
Referenced by the price of 1 transaction in Table I.
- F6
The RSUs were granted on March 26, 2025 as earnout RSUs pursuant to the BCA. The BCA provided that certain optionholders would receive RSUs of the issuer, determined in accordance with a formula set forth in the BCA and for no additional consideration, if a certain clinical development milestone was achieved within five years of the Closing Date. The Reporting Person's right to receive the earnout RSUs became fixed and irrevocable on the Closing Date.
Referenced by the price of 2 transactions in Table II.